Shandong Buchang Pharmaceuticals (603858) Stock Overview
Shandong Buchang Pharmaceuticals Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
603858 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Shandong Buchang Pharmaceuticals Co., Ltd. Competitors
Tonghua Dongbao Pharmaceutical
Shenzhen Hepalink Pharmaceutical Group
Shanghai Shyndec Pharmaceutical
Tonghua Golden-Horse Pharmaceutical Industry CoLtd
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥16.85 |
| 52 Week High | CN¥20.58 |
| 52 Week Low | CN¥13.83 |
| Beta | 0.51 |
| 1 Month Change | -3.05% |
| 3 Month Change | 1.87% |
| 1 Year Change | 11.89% |
| 3 Year Change | -12.29% |
| 5 Year Change | -25.48% |
| Change since IPO | -64.61% |
Recent News & Updates
Recent updates
Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?
Dec 31
Investors Aren't Buying Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues
Dec 04The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet
Aug 26Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?
Jul 29Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S
Apr 27We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt
Feb 28Shareholder Returns
| 603858 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.2% | -0.4% | -2.9% |
| 1Y | 11.9% | 11.5% | 25.0% |
Return vs Industry: 603858 matched the CN Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: 603858 underperformed the CN Market which returned 25% over the past year.
Price Volatility
| 603858 volatility | |
|---|---|
| 603858 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 603858 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603858's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 7,689 | Chao Zhao | www.buchang.com |
Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China.
Shandong Buchang Pharmaceuticals Co., Ltd. Fundamentals Summary
| 603858 fundamental statistics | |
|---|---|
| Market cap | CN¥17.50b |
| Earnings (TTM) | CN¥1.66m |
| Revenue (TTM) | CN¥10.96b |
Is 603858 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603858 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.96b |
| Cost of Revenue | CN¥4.09b |
| Gross Profit | CN¥6.87b |
| Other Expenses | CN¥6.86b |
| Earnings | CN¥1.66m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | 0.0016 |
| Gross Margin | 62.65% |
| Net Profit Margin | 0.015% |
| Debt/Equity Ratio | 36.1% |
How did 603858 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 16:29 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shandong Buchang Pharmaceuticals Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiaxi Xu | Industrial Securities Co. Ltd. |